PMLiVE6d
Chiesi Group invests €400m to establish biotech centre of excellence in Italy
Chiesi Group has announced the operational launch of its biotech centre of excellence in Italy. The company has invested ...
PMLiVE6d
Bristol Myers Squibb’s Opdivo regimen granted FDA approval in NSCLC
Bristol Myers Squibb’s Opdivo (nivolumab) has been approved by the US Food and Drug Administration (FDA) as part of a ...
PMLiVE7d
Unlocking innovation: The power of diversity at Mednet
Diversity and inclusion are critical to business success, particularly when fostering innovation and creativity. At Mednet, ...
PMLiVE7d
GSK receives CHMP recommendation for meningococcal disease vaccine Menveo
GSK has received a recommendation from the European Medicines Agency’s human medicines committee for a single-vial, fully liquid presentation of its meningococcal vaccine Menveo. The new presentation, ...
PMLiVE13d
FDA grants rare paediatric disease designation to Enterprise’s cystic fibrosis candidate
The US Food and Drug Administration (FDA) has granted rare paediatric disease (RPD) designation to Enterprise Therapeutics’ investigational cystic fibrosis therapy. Estimated to affect more than ...
PMLiVE7d
Results from Global Pharmaceutical Customer Experience survey
Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...
PMLiVE9d
Roche’s injectable C5 inhibitor PiaSky recommended by NICE for rare blood disorder PNH
Roche’s injectable component C5 inhibitor has been recommended by the National Institute for Health and Care Excellence (NICE) to treat the rare blood disorder paroxysmal nocturnal haemoglobinuria ...
PMLiVE15d
The partnership triangle
The marketeer wants the agency it knows and trusts, not the ones on the list; the agency has spent a fortune on a pitch only to find the budget is a fraction of that suggested and the plan has changed ...
PMLiVE13d
UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa
UCB has shared positive two-year results for its inflammatory disease drug Bimzelx (bimekizumab) in moderate-to-severe hidradenitis suppurativa (HS). New data from the phase 3 BE HEARD I and BE HEARD ...
PMLiVE9d
Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension
Johnson & Johnson’s (J&J) Yuvanci (single tablet combination therapy [STCT] of macitentan and tadalafi) has been approved by the European Commission (EC) as a long-term treatment for pulmonary ...
PMLiVE10d
Ipsen’s Kayfanda granted EC approval to treat cholestatic pruritus in Alagille syndrome
Ipsen’s Kayfanda (odevixibat) has been approved by the European Commission (EC) under exceptional circumstances to treat cholestatic pruritus in Alagille syndrome (ALGS) patients aged six months and ...
PMLiVE16d
Sanofi/Regeneron’s Dupixent recommended by CHMP for younger eosinophilic oesophagitis patients
Sanofi and Regeneron’s Dupixent (dupilumab) has been recommended by the European Medicines Agency’s human medicines committee to treat younger eosinophilic oesophagitis (EoE) patients. The Committee ...